Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143

Cancer Sci. 2018 May;109(5):1455-1467. doi: 10.1111/cas.13559. Epub 2018 Apr 14.

Abstract

Despite considerable research on K-Ras inhibitors, none had been established until now. We synthesized nuclease-resistant synthetic miR-143 (miR-143#12), which strongly silenced K-Ras, its effector signal molecules AKT and ERK, and the K-Ras activator Sos1. We examined the anti-proliferative effect of miR-143#12 and the mechanism in human colon cancer DLD-1 cell (G13D) and other cell types harboring K-Ras mutations. Cell growth was markedly suppressed in a concentration-dependent manner by miR-143#12 (IC50 : 1.32 nmol L-1 ) with a decrease in the K-Ras mRNA level. Interestingly, this mRNA level was also downregulated by either a PI3K/AKT or MEK inhibitor, which indicates a positive circuit of K-Ras mRNA expression. MiR-143#12 silenced cytoplasmic K-Ras mRNA expression and impaired the positive circuit by directly targeting AKT and ERK mRNA. Combination treatment with miR-143#12 and a low-dose EGFR inhibitor induced a synergistic inhibition of growth with a marked inactivation of both PI3K/AKT and MAPK/ERK signaling pathways. However, silencing K-Ras by siR-KRas instead of miR-143#12 did not induce this synergism through the combined treatment with the EGFR inhibitor. Thus, miR-143#12 perturbed the K-Ras expression system and K-Ras activation by silencing Sos1 and, resultantly, restored the efficacy of the EGFR inhibitors. The in vivo results also supported those of the in vitro experiments. The extremely potent miR-143#12 enabled us to understand K-Ras signaling networks and shut them down by combination treatment with this miRNA and EGFR inhibitor in K-Ras-driven colon cancer cell lines.

Keywords: K-Ras; Ras inhibitor; Sos1; epidermal growth factor receptor; miR-143.

MeSH terms

  • Animals
  • Benzimidazoles / administration & dosage
  • Benzimidazoles / pharmacology
  • Benzothiazoles / administration & dosage
  • Benzothiazoles / pharmacology
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / genetics
  • Drug Synergism
  • Flavonoids / administration & dosage
  • Flavonoids / pharmacology
  • HT29 Cells
  • Humans
  • Mice
  • MicroRNAs / administration & dosage*
  • MicroRNAs / antagonists & inhibitors
  • MicroRNAs / chemical synthesis*
  • MicroRNAs / chemistry
  • MicroRNAs / pharmacology
  • Mutation
  • Neoplasm Transplantation
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / pharmacology
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Signal Transduction / drug effects

Substances

  • 5233705 compound
  • Benzimidazoles
  • Benzothiazoles
  • Flavonoids
  • KRAS protein, human
  • MIRN143 microRNA, human
  • MicroRNAs
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins p21(ras)
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one